IGFBP7 is a p53 target gene inactivated in human lung cancer by DNA hypermethylation

Lung Cancer

Volumn 73, Issue 1, 2011, Pages 38-44

  Chen, Yuan ^a   Cui, Tiantian ^a   Knösel, Thomas ^a   Yang, Linlin ^a   Zöller, Kristin ^a   Petersen, Iver ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Adriamycin; IGFBP7; Methylation; P53; Primary lung tumor; Survival time

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; DNA; DOXORUBICIN; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DATA ANALYSIS; DEMETHYLATION; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; EXPRESSION VECTOR; GENE INACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STAINING;

ADENOCARCINOMA; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CELL LINE; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79957708438     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.10.015     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
2. Berrino F., Capocaccia R., Estève J., Gatta G., Hakulinen T., Micheli A., et al. Survival of cancer patients in Europe: The EUROCARE-2 Study. IARC Scientific Publications No. 152 1999, International Agency for Research on Cancer, Lyon, p. 1-589.
3. Kim J.S., Kim J.W., Han J., Shim Y.M., Park J., Kim D.H. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 2006, 66:4049-4054.
4. Kaira K., Sunaga N., Tomizawa Y., Yanagitani N., Ishizuka T., Saito R., et al. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers. Int J Oncol 2007, 31:169-173.
5. Yendamuri S., Trapasso F., Ferracin M., Cesari R., Sevignani C., Shimizu M., et al. Tumor suppressor functions of ARLTS1 in lung cancers. Cancer Res 2007, 67:7738-7745.
6. Chen Y., Pacyna-Gengelbach M., Ye F., Knosel K., Lund P., Deutschmann N., et al. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer. J Pathol 2007, 211:431-438.
7. Burger A.M., Leyland-Jones B., Baneriee K., Spyropoulos D.D., Seth A.K. Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer 2005, 41:1515-1527.
8. Akaogi K., Sato J., Okabe Y., Sakamoto Y., Yasumitsu H., Miyazaki K. Synergistic growth stimulation of mouse fibroblasts by tumor-derived adhesion factor with insulin-like growth factors and insulin. Cell Growth Differ 1996, 7:1671-1677.
9. Wilson H.M., Birnbaum R.S., Poot M., Quinn L.S., Swisshelm K. Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth Differ 2002, 13:205-213.
10. Walker G.E., Antoniono R.J., Ross H.J., Paisley T.E., Oh Y. Neuroendocrine-like differentiation of non-small cell lung carcinoma cells: regulation by cAMP and the interaction of mac25/IGFBP-rP1 and 25.1. Oncogene 2006, 25:1943-1954.
11. Sato Y., Chen Z., Miyazaki K. Strong suppression of tumor growth by insulin-like growth factor-binding protein-related protein 1/tumor-derived cell adhesion factor/mac25. Cancer Sci 2007, 98:1055-1063.
12. Swisshhelm K., Ryan K., Tsuchiya K., Sager R. Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. Proc Natl Acad Sci U S A 1995, 92:4472-4476.
13. Pereira R.C., Blanquaert F., Canalis E. Cortisol enhances the expression of mac25/insulin-like growth factor-binding protein-related protein-1 in cultured osteoblasts. Endocrinology 1999, 140:228-232.
14. Pen A., Moreno M.J., Durocher Y., Deb-Rinker P., Stanimirovic D.B. Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-beta signaling. Oncogene 2008, 27:6834-6844.
15. Wajapeyee N., Serra R.W., Zhu X., Mahalingam M., Green M.R. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008, 132:363-374.
16. Wajapeyee N., Kapoor V., Mahalingam M., Green M.R. Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Mol Cancer Ther 2009, 8:3009-3014.
17. Suzuki H., Igarashi S., Nojima M., Maruyama R., Yamamoto E., Kai M., et al. IGFBP7 is a p53 responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis 2009, 31:342-349.
18. Smith P., Nicholson L.J., Syed N., Payne A., Hiller L., Garrone O., et al. Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes. Clin Cancer Res 2007, 13:4061-4068.
19. Chen Y., Knösel T., Kristiansen G., Pietas A., Garber M.E., Matsuhashi S., et al. I. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol 2003, 200:640-646.
20. Difilippantonio S., Chen Y., Pietas A., Schlüns K., Pacyna-Gengelbach M., Deutschmann N., et al. Gene expression profiles in human non-small and small-cell lung cancers. Eur J Cancer 2003, 39:1936-1947.
21. Komatsu S., Okazaki Y., Tateno M., Kawai J., Konno H., Kusakabe M., et al. Methylation and downregulated expression of mac25/insulin-like growth factor binding protein-7 is associated with liver tumorigenesis in SV40T/t antigen transgenic mice, screened by restriction landmark genomic scanning for methylation (RLGS-M). Biochem. Biophys Res Commun 2000, 267:109-117.
22. Yamashita S., Tsujino Y., Moriguchi K., Tatematsu M., Ushijima T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci 2006, 97:64-71.
23. Ye F., Chen Y., Knösel T., Schlüns K., Pacyna-Gengelbach M., Deutschmann N., et al. Decreased expression of insulin-like growth factor binding protein 7 in human colorectal carcinoma is related to DNA methylation. J Cancer Res Clin Oncol 2007, 133:305-314.
24. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B.R., et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995, 377:646-649.
25. Suzuki H., Itoh F., Toyota M., Kikuchi T., Kakiuchi H., Imai K. Inactivation of the 14-3-3 sigma gene is associated with 5' CpG island hypermethylation in human cancers. Cancer Res 2000, 60:4353-4357.
26. Wales M.M., Biel M.A., Deiry W., Nelkin B.D., Issa J.P., Cavenee W.K., et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1995, 1:570-577.
27. Christoph F., Weikert S., Kempkensteffen C., Krause H., Schostak M., Köllermann J., et al. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin Cancer Res 2006, 12:5040-5046.
28. Schrump D.S., Fischette M.R., Nguyen D.M., Zhao M., Li X., Kunst T.F., et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006, 12:5777-5785.
29. Momparler R.L., Bouffard D.Y., Momparler L.F., Dionne J., Belanger K., Ayoub J. Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997, 8:358-368.
30. Schwartsmann G., Schunemann H., Gorini C.N., Filho A.F., Garbino C., Sabini G., et al. I. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 2000, 18:83-91.